Understand the source comparison
Best Peptides for Parkinson's Support: Research Compound Comparison
Cerebrolysin BDNF/GDNF upregulation in dopaminergic neurons High (mixture of low-MW neuropeptides) 30mL IV infusion, 5×/week for 4 weeks Multiple Phase III trials, meta-analysis published Strongest clinical evidence for adjunct neuroprotection P21 CREB pathway
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Cerebrolysin
- BDNF/GDNF upregulation in dopaminergic neurons
- High (mixture of low-MW neuropeptides)
- 30mL IV infusion, 5×/week for 4 weeks
- Multiple Phase III trials, meta-analysis published
- Strongest clinical evidence for adjunct neuroprotection
- P21
- CREB pathway activation, synaptic plasticity enhancement
- Moderate (small peptide, requires active transport)
- 1mg/kg SC daily for 14–21 days (rodent models)
- Preclinical only, no human RCTs
- Promising for compensatory circuit function, needs clinical validation
- Thymalin
- Immune modulation, reduced microglial activation
- Low (acts peripherally on T-cells, indirect CNS effect)
- 10mg IM, 2–3×/week for 4–6 weeks
- Immunology research, limited neurology-specific data
- Addresses neuroinflammation indirectly, best as adjunct to primary neuroprotectant
- Dihexa
- HGF receptor agonism, BDNF signalling amplification
- Very high (lipophilic structure)
- 0.5–2mg/kg SC (rodent models)
- Early preclinical, no Phase II data
- Potent but requires microgram-precision dosing, high risk of dosing error
- MK-677
- Growth hormone secretagogue, IGF-1 elevation
- Moderate (oral bioavailability)
- 25mg oral daily
- Phase II trials in aging, not Parkinson's-specific
- Supports general neuroprotection via IGF-1, not targeted to dopaminergic pathways